Tetradecanoylcarnitine
Based on 1 Customer Validation
Tetradecanoylcarnitine is an acylcarnitine involved in mitochondrial β-oxidation of long-chain saturated fatty acids and fatty acid metabolism. Tetradecanoylcarnitine serves as a biomarker for very long-chain acyl-CoA dehydrogenase deficiency and MPTP (HY-15608)-induced Parkinson's disease. Tetradecanoylcarnitine exhibits a characteristic significant elevation in plasma levels in patients with sarcopenia, including those complicated with hypertension, and this elevation is closely associated with an increased risk of death. Tetradecanoylcarnitine is widely used in research on the pathological mechanisms of diseases such as Parkinson's disease and sarcopenia.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 25597-07-3
- Formula: C21H41NO4
- Molecular Weight:371.55
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Human Endogenous Metabolite |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 25597-07-3
-
Appearance Solid
-
Molecular Weight 371.55
-
Formula C21H41NO4
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 100 mg/mL (269.14 mM; Need ultrasonic)
DMSO : 25 mg/mL (67.29 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li XZ, et al. Cerebral metabonomics study on Parkinson's disease mice treated with extract of Acanthopanax senticosus harms. Phytomedicine. 2013;20(13):1219-1229. [Content Brief]
[2]. Ho HY, et al. Combined Plasma DHA-Containing Phosphatidylcholine PCaa C38:6 and Tetradecanoyl-Carnitine as an Early Biomarker for Assessing the Mortality Risk among Sarcopenic Patients. Nutrients. 2024;16(5):611. Published 2024 Feb 23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.6914 mL | 13.4571 mL | 26.9143 mL | 67.2857 mL |
| 5 mM | 0.5383 mL | 2.6914 mL | 5.3829 mL | 13.4571 mL | |
| 10 mM | 0.2691 mL | 1.3457 mL | 2.6914 mL | 6.7286 mL | |
| 15 mM | 0.1794 mL | 0.8971 mL | 1.7943 mL | 4.4857 mL | |
| 20 mM | 0.1346 mL | 0.6729 mL | 1.3457 mL | 3.3643 mL | |
| 25 mM | 0.1077 mL | 0.5383 mL | 1.0766 mL | 2.6914 mL | |
| 30 mM | 0.0897 mL | 0.4486 mL | 0.8971 mL | 2.2429 mL | |
| 40 mM | 0.0673 mL | 0.3364 mL | 0.6729 mL | 1.6821 mL | |
| 50 mM | 0.0538 mL | 0.2691 mL | 0.5383 mL | 1.3457 mL | |
| 60 mM | 0.0449 mL | 0.2243 mL | 0.4486 mL | 1.1214 mL | |
| H2O | 80 mM | 0.0336 mL | 0.1682 mL | 0.3364 mL | 0.8411 mL |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2691 mL | 0.6729 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
- Tetradecanoylcarnitine
- 25597-07-3
- Endogenous Metabolite
- MPTP-induced Parkinson’s disease mice
- Acanthopanax senticosus harms extract
- hypertension
- mitochondrial beta-oxidation
- long-chain saturated fatty acids
- sarcopenic patients
- very long-chain acyl-CoA dehydrogenase deficiency
- Parkinson’s disease
- sarcopenia
- fatty acid metabolism
- Inhibitor
- inhibitor
- inhibit